ELEDON PHARMACEUTICALS INC. - COMMON STOCK

Eledon Pharmaceuticals Announces Orphan Drug Designation Granted to Tegoprubart for the Prevention of Allograft Rejection in Pancreatic Islet Cell Transplantation

09 Jun 2022 08:00:01 By Nasdaq GlobeNewswire

Eledon Pharmaceuticals to Present at the Jefferies Healthcare Conference

02 Jun 2022 16:05:00 By Nasdaq GlobeNewswire

Eledon Announces Positive Topline Results from Phase 2a Trial of Tegoprubart Demonstrating Safety, Target Engagement, and Biomarker Response in Patients Living with Amyotrophic Lateral Sclerosis

31 May 2022 06:00:00 By Nasdaq GlobeNewswire

Eledon Pharmaceuticals Reports First Quarter 2022 Operating and Financial Results

12 May 2022 16:01:00 By Nasdaq GlobeNewswire

Eledon Pharmaceuticals Announces First Patient Dosed in Phase 2a Trial Evaluating Tegoprubart in IgA Nephropathy

09 May 2022 08:00:02 By Nasdaq GlobeNewswire

Eledon Pharmaceuticals to Report First Quarter 2022 Financial Results on Thursday, May 12, 2022

05 May 2022 16:05:00 By Nasdaq GlobeNewswire

Eledon Pharmaceuticals to Participate in LifeSci Partners Immunology & Inflammation Symposium

03 May 2022 16:05:00 By Nasdaq GlobeNewswire

Eledon Pharmaceuticals to Participate in 18th Annual Noble Capital Markets Investor Conference

18 Apr 2022 16:05:00 By Nasdaq GlobeNewswire

Eledon to Host Virtual R&D Day on Thursday, April 28, 2022

14 Apr 2022 16:05:00 By Nasdaq GlobeNewswire

Eledon Pharmaceuticals Reports Fourth Quarter and Full-Year 2021 Operating and Financial Results

24 Mar 2022 16:01:00 By Nasdaq GlobeNewswire

Eledon Pharmaceuticals to Report Fourth Quarter and Full Year 2021 Financial Results on Thursday, March 24, 2022

17 Mar 2022 08:00:02 By Nasdaq GlobeNewswire

Eledon Pharmaceuticals Provides Corporate Update and 2022 Outlook

14 Feb 2022 08:00:01 By Nasdaq GlobeNewswire

Eledon Pharmaceuticals to Participate in 11th Annual SVB Leerink Global Healthcare Conference

08 Feb 2022 16:05:00 By Nasdaq GlobeNewswire